Spotlight
Topics
DI Executive
Subscribe
- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
CT-Based Staging System for Coronary Artery Disease Gets FDA's Breakthrough Device Designation
Employing quantitative computed tomography, the staging system’s insights on stenosis, ischemia and coronary atherosclerosis may facilitate individualized assessments of heart disease risk.
The Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Cleerly’s Coronary Artery Disease (CAD) Staging System.
Offering a four-stage approach that incorporates total plaque volume (TPV) and percent atheroma volume (PAV) assessments from quantitative computed tomography (CT), Cleerly said the CAD Staging System provides insights into actionable aspects of stenosis, ischemia, and coronary atherosclerosis.
Cleerly's Coronary Artery Disease (CAD) Staging System, which offers a four-stage approach for assessing individual heart disease risk, received Breakthrough Device Designation from the Food and Drug Administration (FDA). (Images courtesy of the Journal of Cardiovascular Computed Tomography.)
Emphasizing the system’s potential for providing individual risk assessments for heart disease, Cleerly added that a randomized controlled trial (TRANSFORM) will assess use of the CAD Staging System for patients with diabetes, pre-diabetes or metabolic syndrome who are currently asymptomatic for heart disease.
“As our Cleerly CAD Staging System becomes available to physicians and patients, it will provide the rationale for preventive tailored treatment of CAD with risk-based therapy goals,” said Udo Hoffmann, M.D., M.P.H., the chief scientific officer of Cleerly.
Recent Videos
Related Content
New Study Assesses Benefits of High-Resolution Photon-Counting for Computed Tomography Angiography
October 10th 2024Article
Researchers found that ultra-high resolution photon-counting significantly enhanced visualization of small vessels and facilitated improved reduction of blooming artifacts for head and neck computed tomography angiography (CTA) scans.
FDA Clears Software for Enhancing CCTA Assessment of Atherosclerosis
October 1st 2024Article
Through analysis of coronary computed tomography angiography (CCTA) images, the PlaqueIQ software provides quantification and classification of atherosclerosis, a common cause of myocardial infarction (MI) and ischemic stroke.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020Podcast
In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Intestinal Ultrasound Provide an Alternative for Evaluating Creeping Fat with Crohn’s Disease?
September 25th 2024Article
Intestinal ultrasound demonstrated an 88.2 percent agreement with computed tomography enterography in characterizing creeping fat in patients with Crohn’s disease, according to new research.
